Related Experiment Videos
The subtle side to hypoxia inducible factor (HIFalpha) regulation
Rebecca L Bilton1, Grant W Booker
1Department of Molecular Biosciences, The University of Adelaide, Australia.
European Journal of Biochemistry
|February 27, 2003
Summary
Hypoxia-inducible factor alpha (HIFalpha) regulates cellular responses to oxygen. Receptor-mediated signals, independent of oxygen levels, also activate HIFalpha through pathways like Akt and MAPK, influencing protein stability and activity.
Area of Science:
- Cellular Biology
- Molecular Biology
- Biochemistry
Background:
- Hypoxia-inducible factor alpha (HIFalpha) is a key transcription factor responding to cellular hypoxia.
- Hydroxylation of HIFalpha by hydroxylase enzymes acts as an oxygen-sensing mechanism.
- Hypoxia prevents HIFalpha modification, increasing its stability and transcriptional activity.
Purpose of the Study:
- To review the mechanisms and functions of receptor-mediated signals in HIFalpha regulation.
- To explore how non-hypoxic factors influence HIFalpha activity.
- To elucidate the role of growth factors, cytokines, and oncogenes in HIFalpha activation.
Main Methods:
- Literature review of existing research on HIFalpha regulation.
- Analysis of signaling pathways involved in HIFalpha activation (e.g., Akt, MAPK).
- Examination of oxygen-dependent and -independent mechanisms controlling HIFalpha.
Main Results:
- Receptor-mediated signals (growth factors, cytokines, oncogenes) activate HIFalpha under normoxic conditions.
- These signals operate via hypoxia-independent pathways, primarily phosphatidyl-inositol-3-kinase/Akt and mitogen-activated protein kinase (MAPK).
- Akt activation increases HIFalpha protein synthesis and activity; MAPK affects synthesis and potentially transcriptional activity.
Conclusions:
- Receptor-mediated signaling provides a multifaceted layer of HIFalpha regulation beyond oxygen levels.
- Understanding these pathways is crucial for comprehending cellular adaptation and disease states.
- Targeting these pathways may offer therapeutic strategies for conditions involving aberrant HIFalpha activity.